风险分层乳腺癌筛查的成本效益与获益-危害比:生命表模型
该生命表模型模拟英国364 500名50岁女性至85岁,比较不筛查、年龄筛查和风险分层筛查。风险分层筛查在70百分位阈值时净货币效益最高,且可减少过度诊断并保持筛查获益。
要点
- 风险分层筛查在70百分位阈值时净货币效益最高
- 降低风险阈值不增加QALY且成本线性增加
- 对低风险女性不筛查可提高成本效益并减少过度诊断
核心结论
- 对低风险女性不提供乳腺癌筛查可提高筛查项目的成本效益、减少过度诊断并保持筛查获益。
研究设计与样本
- 研究为生命表模型,模拟英国364 500名50岁女性,随访至85岁,采用英国独立乳腺癌筛查小组结果和多基因风险分布,从NHS视角分析。
主要发现
- 风险阈值降低时,项目增量成本较不筛查线性增加,但在低于35百分位风险阈值时无额外QALY增益。
- 在支付意愿为每QALY 20 000英镑(26 800美元)时,70百分位风险阈值的风险分层筛查净货币效益最高,成本有效的概率为72%。
- 与年龄筛查相比,32百分位与70百分位风险阈值的风险分层筛查分别节省20 066英镑(26 888美元)与537 985英镑(720 900美元),过度诊断分别减少26.7%与71.4%,乳腺癌死亡分别减少2.9%与9.6%。
关键数值与推荐
- 风险分层筛查定义为对50岁时风险评分高于阈值风险的一定比例女性提供每3年一次筛查至69岁。
- 年龄筛查为50至69岁每3年一次乳腺X线筛查。
- 未来成本和获益按每年3.5%贴现。
临床怎么用
- 可考虑对低风险女性不提供乳腺癌筛查,以优化成本效益并减少过度诊断。
- 风险分层筛查策略可选择70百分位作为风险阈值,以最大化净货币效益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The age-based or "one-size-fits-all" breast screening approach does not take into account the individual variation in risk. Mammography screening reduces death from breast cancer at the cost of overdiagnosis. Identifying risk-stratified screening strategies with a more favorable ratio of overdiagnoses to breast cancer deaths prevented would improve the quality of life of women and save resources. OBJECTIVE: To assess the benefit-to-harm ratio and the cost-effectiveness of risk-stratified breast screening programs compared with a standard age-based screening program and no screening. DESIGN, SETTING, AND POPULATION: A life-table model was created of a hypothetical cohort of 364 500 women in the United Kingdom, aged 50 years, with follow-up to age 85 years, using (1) findings of the Independent UK Panel on Breast Cancer Screening and (2) risk distribution based on polygenic risk profile. The analysis was undertaken from the National Health Service perspective. INTERVENTIONS: The modeled interventions were (1) no screening, (2) age-based screening (mammography screening every 3 years from age 50 to 69 years), and (3) risk-stratified screening (a proportion of women aged 50 years with a risk score greater than a threshold risk were offered screening every 3 years until age 69 years) considering each percentile of the risk distribution. All analyses took place between July 2016 and September 2017. MAIN OUTCOMES AND MEASURES: Overdiagnoses, breast cancer deaths averted, quality-adjusted life-years (QALYs) gained, costs in British pounds, and net monetary benefit (NMB). Probabilistic sensitivity analyses were used to assess uncertainty around parameter estimates. Future costs and benefits were discounted at 3.5% per year. RESULTS: The risk-stratified analysis of this life-table model included a hypothetical cohort of 364 500 women followed up from age 50 to 85 years. As the risk threshold was lowered, the incremental cost of the program increased linearly, compared with no screening, with no additional QALYs gained below 35th percentile risk threshold. Of the 3 screening scenarios, the risk-stratified scenario with risk threshold at the 70th percentile had the highest NMB, at a willingness to pay of £20 000 (US $26 800) per QALY gained, with a 72% probability of being cost-effective. Compared with age-based screening, risk-stratified screening at the 32nd percentile vs 70th percentile risk threshold would cost £20 066 (US $26 888) vs £537 985 (US $720 900) less, would have 26.7% vs 71.4% fewer overdiagnoses, and would avert 2.9% vs 9.6% fewer breast cancer deaths, respectively. CONCLUSIONS AND RELEVANCE: Not offering breast cancer screening to women at lower risk could improve the cost-effectiveness of the screening program, reduce overdiagnosis, and maintain the benefits of screening.
引用
- Pashayan N, Morris S, Gilbert FJ, et al. Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model. JAMA Oncol. 2018. PMID: 29978189. doi:10.1001/jamaoncol.2018.1901
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。